Taysha Gene Therapies Inc (TSHA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Taysha Gene Therapies Inc (TSHA) has a cash flow conversion efficiency ratio of -0.193x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.88 Million) by net assets ($211.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TSHA equity to assets ratio to measure how much of total assets are equity-financed.
Taysha Gene Therapies Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Taysha Gene Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TSHA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Taysha Gene Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taysha Gene Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Changzheng Engineering Co Ltd
SHG:603698
|
-0.046x |
|
Gestamp Automocion SA
MC:GEST
|
0.031x |
|
Interparfums SA
PA:ITP
|
0.197x |
|
Datang International Power Generation Co. Ltd
F:BJI
|
0.037x |
|
L&F Co. Ltd
KQ:066970
|
0.167x |
|
LTC Properties Inc
NYSE:LTC
|
0.026x |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
0.057x |
|
Iljin Electric Co
KO:103590
|
-0.143x |
Annual Cash Flow Conversion Efficiency for Taysha Gene Therapies Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Taysha Gene Therapies Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Taysha Gene Therapies Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $246.94 Million | $-93.09 Million | -0.377x | +66.80% |
| 2024-12-31 | $71.53 Million | $-81.22 Million | -1.136x | -16.55% |
| 2023-12-31 | $74.94 Million | $-73.02 Million | -0.974x | +98.95% |
| 2022-12-31 | $949.00K | $-88.39 Million | -93.140x | -7490.43% |
| 2021-12-31 | $95.38 Million | $-117.04 Million | -1.227x | -903.50% |
| 2020-12-31 | $251.30 Million | $-30.73 Million | -0.122x | +87.77% |
| 2019-12-31 | $-135.00K | $135.00K | -1.000x | -- |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 … Read more